Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A synthetic non-phosphopeptide derived from human EPHB1/2/3/4 around the phosphorylation site of Tyr600/602/614/596 (F-T-YP-E-D)|
|Purification||Antigen affinity chromatography|
|Storage buffer||Dulbecco's PBS, pH 7.4, with 150mM NaCl, 50% glycerol|
|Contains||0.02% sodium azide|
|Tested Applications||Dilution *|
|Western Blot (WB)||1:500-1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Ephrin receptors and their ligands, the ephrins, mediate numerous developmental processes, particularly in the nervous system. Based on their structures and sequence relationships, ephrins are divided into the ephrin-A (EFNA) class, which are anchored to the membrane by a glycosylphosphatidylinositol linkage, and the ephrin-B (EFNB) class, which are transmembrane proteins. The Eph family of receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family. EphB4 binds to ephrin-B2 and plays an essential role in vascular development.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
CAPB; developmental kinase 2; developmental kinase 5; developmentally-regulated Eph-related tyrosine kinase; EK6; elk-related tyrosine kinase; embryonic kinase 2; eph tyrosine kinase 2; eph tyrosine kinase 3; EPH-like kinase 5; EPH-like kinase 6; EPH-like tyrosine kinase 2; EPHB2, Ephrin type-B receptor 1; EPHB3, DRT; ephrin receptor EphB4; ephrin type-B receptor 1; ephrin type-B receptor 2; ephrin type-B receptor 3; ephrin type-B receptor 4; EPHT3; ERK; ETK2; HEK2; Hek5; hepatoma transmembrane kinase; human embryo kinase 2; mDK-2; mDK-5; MGC87492; NET, HEK-6, ELK, Ephrin type-B receptor 2, Ephrin type-B receptor 3, Ephrin B1, EphrinB1, EphrinB3, Ephrin B3, Ephrin B2, EphrinB2, Ephrin B4, EphrinB4, Ephrin type-B receptor 4; neural kinase; neuronally-expressed EPH-related tyrosine kinase; nuk receptor tyrosine kinase; PCBC; protein-tyrosine kinase HEK5; renal carcinoma antigen NY-REN-47; soluble EPHB1 variant 1; soluble EPHB4 variant 1; soluble EPHB4 variant 2; soluble EPHB4 variant 3; Tyro5; TYRO6; tyrosine kinase MYK-1; tyrosine-protein kinase receptor EPH-2; tyrosine-protein kinase receptor EPH-3; tyrosine-protein kinase receptor HTK; tyrosine-protein kinase receptor SEK-3; tyrosine-protein kinase receptor SEK-4; tyrosine-protein kinase TYRO11; tyrosine-protein kinase TYRO5; tyrosine-protein kinase TYRO6
9330129L11; AI042935; AW456895; AW488255; C130099E04Rik; CAPB; Cek10; Cek5; Cek6; DRT; EK2; EK5; ELK; Elkh; ENSMUSG00000074119; EPHB1; EPHB2; EPHB3; EPHB4; EPHT2; EPHT3; EPTH3; ERK; ETECK; ETK2; HEK2; HEK5; HEK6; HTK; MDK2; MDK5; MYK1; NET; Nuk; PCBC; Prkm5; Qek5; Sek3; Sek4; TYRO11; TYRO5; TYRO6